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Abstract
The goal of this PhD research project is to devise a robust interatomic potential for large-
scale molecular dynamics simulations of carbon materials under extreme conditions. This
screened-environment dependent reactive empirical bond order potential (SED-REBO) is
specifically designed to describe carbon materials under extreme compressive or tensile
stresses. Based on the original REBO potential by Brenner and co-workers, SED-REBO
includes reparametrized pairwise interaction terms and a new screening term, which serves
the role of a variable cutoff. The SED-REBO potential overcomes the deficiencies found
with the most commonly used interatomic potentials for carbon: the appearance of arti-
ficial forces due to short cutoff that are known to create erroneous phenomena including
ductile fracture of graphene and carbon nanotubes, which contradicts the experimentally
observed brittle character of these materials. SED-REBO was applied in large scale molec-
ular dynamics simulations of nanoindentation of graphene membranes and shock-induced
compression of diamond. It was shown in the first computational experiment that graphene
membranes exhibit a non-linear response to large magnitude of indentation, followed by a
brittle fracture in agreement with experiments. The strength of graphene was determined
using the kinetic theory of fracture, and the crack propagation mechanisms in the material
were identified. It was found in large-scale shock simulations that SED-REBO improves
the predictive power of MD simulations of carbon materials at extreme conditions.
vii
Chapter 1
Introduction
The subject study consists of four chapters and given below are brief introductions.
1.1 A Statistical Algorithm For Determining The Optimal Doses Of Drugs: A Five
Parameters Logistic Model
Drug effects are commonly screened with cell lines before animal studies and clinical trials
are conducted. Using the point estimate of the half maximal inhibitory concentration (IC50)
as surrogates, drug potency and cell line sensitivity are determined. In the present study,
we demonstrate how the five parameters logistic(5PL) function performs better over the
four parameters logistic(4PL) and its variants. Specifically, we study the behaviors in each
functions and the improvement in accuracy of concentration estimates(IC50) using the 5PL
over the 4PL as a function of the asymmetry present in the data.
The goal of this chapter is to obtain concentration estimates(IC50) that are as accurate
as possible. We can improve this by the quality of the fit of the data. Two of the reasons
that this can be an issue lies on either pure error or lack-of-fit error. Pure error is identified
as the presence of random variation in the data, and can be reduced by increasing the
number of standard replicates. Lack-of-fit represents an error in the curve modeling of the
data. Unlike the first error, this cannot be reduced by increasing the number of standard
replicates. For example, much immunoassay data have sigmoidal, or "s", shapes, if the data
are taken over a wide enough concentration ranges. If a straight line is used as the curve
model to fit such data, fitting data would be the main issue simply because a straight line
cannot fit the curved shape.
1
Bias is introduced into the dose estimates when the quality of the fit of the data is low.
Accuracy is also reduced because over-parameterized curve models have a tendency to
misrepresent the true curve between data points. Over-parameterized models have the ex-
tended problem that they are more susceptible to noise in the responses, which reduces the
precision of dose estimates.
1.2 Survival Analysis of Breast Cancer Data Using the Random Forests: an Ensem-
ble of Trees
Tree-based methods by Bell(1999),[2] have become popular in performing survival anal-
ysis with complex data structures. The data chosen for this study is the SEER data ob-
tained from their website,[8]. Within the Random Forest created by Breiman (2001),[4],
the decision tree analysis by Yuan(1995),[32] was applied to identify the most important
attributable variables which are the major influence in the survival time estimate of a given
cancer patient. Statistically, this information is then extended to develop a statistical model
estimating survival time. This approach proposes to reduce subject estimate prediction
errors using R and My-SQL.
Data mining techniques by Han(2000),[14], have been extensively applied to breast can-
cer diagnosis, predicting the presence of cancer and differentiating between malignant and
benign cases.
WHO statistical reports by D.M. Parkin (2005),[6] report that the incidence of breast
cancer is the number one form of cancer among women. Breast cancer occurs due to
an uncontrolled growth of cells in the breast tissues by BCF,[3] and damage to the cell’s
DNA, National Breast Cancer Center,[22]. A tumor is an abnormal cell growth that can
either be benign or malignant. Benign tumors are non invasive while malignant tumors are
cancerous and spread to other parts of the body. In the United States, approximately one
in eight women have a risk of developing breast cancer over their lifetime. An analysis of
the most recent data has shown that the survival rate is 88% after 5 years of diagnosis and
2
80% after 10 years of diagnosis, AMSWebite,[30]. Early diagnosis and treatment help to
prevent the spreading of cancer.
In this chapter, we used the SEER breast cancer data and introduced the classification
approach according to our research interest. Data mining was also explained as the process
of analyzing large quantities of data and summarizing them into useful information. We
then extended this process to create classified groups and rank attributable variables using
a weighted counting method.
1.3 Estimating the Four Parameters Johnson-SB Probability Distribution: New R
Package
Scientists often experience difficulties in obtaining estimates for the four parameters of the
Johnson SB probability distribution. The Four parameter Johnson SB probability distribu-
tion is very important in parametrically studying a variety of health, environmental, and
engineering problems.
Many methods have been proposed to estimate the parameters of the Johnson SB prob-
ability distribution, one of them being the four percentile method,Wheeler, Slifker and
Shapiro, 1980. Another method to obtain approximate estimates is the Knoebel-Burkhart
method (Knoebel and Burkhart,[27] at 1991)
The aim of the present study is to review such existing methods and their ability to
estimate the four parameters of the subject probability density function. We are proposing
a fast algorithm that produces better approximations for these parameters using numerical
simulations, real cancer data, and normal transformations to generate random numbers and
the Newton-Raphson method. Graphs using R are also drawn up by incorporating general
integration and a prediction procedure. These methods and procedures all come together to
supply the backbone in the effectiveness of our method.
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1.4 Estimating Survival Time of Baseline Lung Cancer Using Statistical Modeling
Lung Cancer is the second leading cause of death and was among one of the first diseases
causally linked to smoking. The relationship between smoking and lung cancer is well
documented (Doll and Peto, 1978; Doll et al., 2004;IARC,2004), along with the benefits of
smoking cessation(US DHHS, 1990; Peto et al., 2000)among other. In the United States,
cigarette smoking causes approximately 438,000 deaths each year, including deaths related
to cancer, cardiovascular disease, respiratory disease and infant mortality [1]. Compared
to nonsmokers, men who smoke are about 23 times more likely to develop lung cancer
and women who smoke are about 13 times more likely. Smoking accounts for 90% of
all cases, making it a major determinant of lung cancer. Many studies have focused on
two hypotheses: whether the combined effect of asbestos and smoking is addictive (each
factor acts independently) or multiplicative (the effect of asbestos exposure on lung cancer
risk is proportional to the effect of smoking) (Doll and Peto, 1985; Hammond et al., 1979;
Lee, 2001). In our research, the purpose is to identify the significant attributable variables
as well as all possible interactions between those variables. We also aim to construct a
statistical model to predict the survival time as a function of those attributable variables and
interactions. In this study, we used the number of cigarettes per day, duration of smoking,
and the age at diagnosis of lung cancer to identify the significant attributable variables,
including their interactions, the survival time, and probability density functions for the
classified groups.
4
Chapter 2
A Statistical Algorithm For Determining The Optimal Doses Of Drugs
2.1 Introduction
Drug effect using cell lines is commonly screened before animal studies and clinical trials
are conducted. The point estimate of the half maximal inhibitory concentration (IC50) is
commonly used as the surrogate for drug potency and cell line sensitivity toward a given
drug. A good method which could provide reliable parameter estimation and biological
interpretability is critical for drug development. Several typical issues associated with es-
timating IC50 using nonlinear statistical models, such as logistic regression, include the
following: control level of cell survival is not always 100% because cells proliferate and
not all the cells are necessarily killed off at the highest given dose (i.e., background-level
cell survival does not always reach 0%). In the present study, we demonstrate how the use
of the five parameters logistic(5PL) function can improve assay performance over the four
parameters logistic(4PL) and its variants. Specifically, the improvement in the accuracy of
concentration estimates(IC50) that can be obtained using the 5PL over the 4PL as a func-
tion of the asymmetry present in the data is studied. The behavior of the 5PL curve and the
4PL curve are discussed.
The goal of this chapter is to obtain concentration estimates(IC50) that are as accurate as
possible by improving the quality of the fit of the data. However, there are two reasons that
the curve will not fit the data perfectly. The first reason is the presence of random variation
in the data. This kind of error is called pure error and can be reduced by increasing the
number of replicates of each standard. The second reason is that the curve model may
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not approximate the true curve very well. This kind of error is called lack-of-fit error and
cannot be reduce by increasing the number of standard replicates. For example, much
immunoassay data have a sigmoidal, or "s", shape, if data are taken over a wide enough
range of concentrations. If a straight line is used as the curve model to fit such data, much
of the error in fitting the data would be due to lack-of-fit error. This is because a straight
line cannot fit the curving sigmoidal shape of the data.
When the curve model is unable to follow the true curve, bias is introduced into the
dose estimates and their accuracy is reduced. Furthermore, because over-parameterized
curve models tend not to represent the true curve very well between data points, accuracy
is reduced in these models, even though such curve models may "fit" the data quite well.
Over-parameterized models have the extended problem that they are more susceptible to
noise in the responses, which reduces the precision of dose estimates.
2.2 The Four Parameter Logistic Model
Logistic functions are useful for drug efficiency modeling. Among all the possible forms
of logistic functions, the four-parameter logistic(4PL) function is the most commonly used
in drug efficiency modeling. The parametric form of this four-parameter function is shown
in equation (2.1) and graphically by Figure 1.
y = D+
A−D
1+( xC)
B , (2.1)
x = f−1(y;A,B,C,D)
= c
(
y−A
D− y −1
) 1
B
,
(2.2)
• A = Minimum asymptote. In a bioassay where you have a standard curve, this can be
6
thought of as the response value at a 0 standard concentration.
• B = Hill’s slope. The Hill’s slope refers to the steepness of the curve. This parameter
controls the speed to the asymptotes. It can either be positive or negative.
• C = Inflection point. The inflection point is defined as the point on the curve where the
curvature changes direction or signs.
• D = Maximum asymptote. In an bioassay where you have a standard curve, this can be
thought of as the response value for infinite standard concentration.
Figure 1.: Four Parameter Logistic Model with A=5, B=5.5, C=5, D=5
To quantify the concentration of the analysis, the response must be compared to a cali-
bration curve, commonly called the ideal curve. The unknown concentration of an analysis
may then be determined by finding the concentration on the standard curve that produces
the same response as that obtained from the unknown sample.
We define a true curve if and only if we have an infinite number of concentrations, each
with an infinite number of replicates. Ideally, the standard curve would be identical to the
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true data curve: the curve that expresses the concentration versus response relationship
without any degradation by errors.
The four-parameter logistic(4PL) function[15] [7] [10] is widely used in practice and is
closely related to the linear logit-log model. However, like the logit-log model, the 4PL
model cannot effectively model asymmetric data. The mass action model [12] the only
physically based model, has many parameters, which makes it less able to average out noise
than models with fewer parameters. It has also been shown that certain approximations to
the mass action model are approximately equivalent to the logit-log model [1], which,
as noted above, implies approximate equivalence to the 4PL curve. Like the 4PL, this
approximation to the full mass action model is unable to fit asymmetric data.
A method that is used to handle asymmetry is the log 4PL method. This method takes
advantage of the fact that taking the logarithm of the response of some asymmetric assay
data can make the data more symmetrical and therefore better suited to a 4PL fit. This
approach can improve the fit when the low response end of a sigmoidal curve has a shorter
tail than the upper end of the curve.
However, taking the log of the responses of sigmoidal data where the responses on the
low response end of the curve approach the lower asymptote more slowly than the responses
on the high response end makes the data more asymmetric. Since this type of behavior is
encountered in immuno assay and bio assay data more often than the former, this approach
is not fit for routine data reduction. Many other curve models have been tried with varying
degrees of success. Space does not permit further discussion here, but Rodbard [10] pro-
vides a useful overview of some of the dose response models that have been discussed in
the literature.
The 4PL function has an assumption of symmetry about the IC50 value which is rarely
tested in many applications. When a curve is unable to accommodate the asymmetry, bias
is introduced into the potency estimate due to lack of fit.
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Recently, the five-parameter logistic(5PL) function has seen increased use as a model
for bioassay dose-response curves with an extra parameter to characterize the curve asym-
metry. This 5PL, as shown by equation 2.2, below, includes the 4PL function as a special
case when G is 1. The 5PL function takes curve asymmetry into consideration to overcome
some drawbacks of the four parameter logistic(4PL) function.
The 4PL model can be extended by adding a fifth parameter that controls the degree
of asymmetry of the curve [25] [20].This is available commercially [5]. With the extra
flexibility afforded by its asymmetrical parameter, the 5PL model is able to virtually elim-
inate the lack-of-fit error that occurs when the 4PL is fitted to asymmetric dose response
data. This chapter focuses on the use of the 5PL model for fitting dose response data. The
5PL model provides an excellent compromise between over-parameterized models that can
fit data closely at the cost of a large variance in the predictions and under-parameterized
models that suffer from large lack-of-fit errors.
2.3 The Five Parameter Logistic Model
The currently used 5PL function is depicted in Equation 2.3, below
y = f (x;p) = f (x;A,B,C,D,g) = D+
A−D((
1+ xc
)B)g , (2.3)
• A = Minimum asymptote. In a bioassay where you have a standard curve, this can be
thought of as the response value at a 0 standard concentration.
• B = Hill’s slope. The Hill’s slope refers to the steepness of the curve. This parameter
controls the speed to the asymptotes. It can either be positive or negative.
• C = Inflection point. The inflection point is defined as the point on the curve where the
curvature changes direction or signs, and must be greater than 0.
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• D = Maximum asymptote. In an bioassay where you have a standard curve, this can be
thought of as the response value for infinite standard concentration.
• g = Jointly with B controls the rate of approach to the D asymptote, and greater than 0.
The 4PL function is obtained by setting g=1.
After the 5PL model has been fitted to standard data, estimates for single-dilution un-
known concentrations x can be obtained from unknown responses y using the inverse of
equation 2.3, that is,
x = f−1(y;p) = f−1(y;A,B,C,D,g)
= c
((
A−D
y−D
) 1
g
−1
) 1
B
,
(2.4)
As we mentioned above, the extra parameter g is introduced for addressing asymmetry.
Both the shape parameter B and parameter g jointly determine the speed for the response
to approach the two asymptotes A and D. Setting g=1 in equation 2.2 reduces to the 4PL
function in equation 2.1, and a median effect of dose(ED50) is given by equation 2.5,
ED50 =C
(
21/g−1
)1/B
. (2.5)
2.4 The Effects of The Five Parameters In The Logistic Model
The 5PL function given by equation 2.3 has been used to improve the performance over the
4PL as given by equation 2.1. When we change a parameter while keeping the others fixed,
the dynamic pattern of the curve change and are not the same as those of the 4PL. Thus,
the parameter effect on the pattern changes of the current 5PL is displayed in the follwoing
graphs, Figures 2.2-2.6
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Figure 2.: The Effect of Parameters A in five parameters logistic model based on y =
D+ A−D(
(1+ xc)
B
)g .
The above Figure 2 shows the behavior of parameter A while fixing B=5, C=5, D=5,and
g=4. This figure also shows the difference between the five parameters and four parameters
logistic curve. The IC50 value in 4PL is 5, and 3.8 in 5PL with A=0 and fixed parameters.
Figure 3.: The Effect of Parameters B in five parameters logistic model based on y =
D+ A−D(
(1+ xc)
B
)g .
The above Figure 3 shows the behavior of parameter B while fixing A=0, C=5, D=5,and
g=4. This figure also shows the difference between the five parameters and four parameters
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logistic curve. The IC50 value in 4PL is 5, and 3.8 in 5PL with B=5.5 and fixed parameters.
Figure 4.: The Effect of Parameters C in five parameters logistic model based on y =
D+ A−D(
(1+ xc)
B
)g .
The above Figure 4 shows the behavior of parameter C while fixing A=0, B=5.5, D=5,and
g=4. This figure also shows the difference between five parameters and four parameters lo-
gistic curve. The IC50 value in 4PL is 5, and 3.8 in 5PL with C=5 and fixed parameters.
Figure 5.: The Effect of Parameters D in five parameters logistic model based on y =
D+ A−D(
(1+ xc)
B
)g .
The above Figure 5 shows the behavior of parameter D while fixing A=0, B=5.5, C=5,
12
D=5,and g=4. This figure also shows the difference between five parameters and four
parameters logistic curve. The IC50 value in 4PL is 5, and 3.8 in 5PL with D=4 and fixed
parameters.
Figure 6.: The Effect of Parameters g in five parameters logistic model based on y =
D+ A−D(
(1+ xc)
B
)g .
The above Figure 6 shows the behavior of parameter g while fixing B=5, C=5, D=5,and
g=4. This figure also shows the difference between five parameters and four parameters
logistic curve. The IC50 value in 4PL is 5, and 3.8 in 5PL with A=0 and fixed parameters.
2.5 Development Of A Statistical Algorithms To Estimate The Five Parameters Lo-
gistic Model
Dose response data can either be asymmetric or symmetric; therefore, we could not apply
four parameters logistic model directly. We proceeded to develop a statistical algorithm to
estimate the five parameters of the logistic model, 2.2. We will accomplish this in develop-
ing the algorithm that will be based on three parts of our modules. A schematic diagram of
the overall proposed drug efficiency modeling in shown by Figure 7
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Figure 7.: Main Modules for Drug Efficiency Program.
The overall structure of the main modules consists of three parts:
• Outlier Replicate Remover.
• Dynamic Initial Value Detection.
• Estimate the parameters of logistic model.
The subject data depends on several replicated experiments; however, there are some
unexpected results that we call outliers. We use the distance algorithm between replicated
experiments to detect outliers. In the parameter estimation, we have the initial value prob-
lem because we need to detect the local maximum or local minium. This is a very common
problem in the estimation procedure. We could easily avoid this problem by using all pos-
sible combinations of the initial starting points, but it is not an efficient way to estimate
parameters. Thus, we proceed to apply dynamic initial values in our program for quick and
accurate estimates.
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The schematic diagram shown by Figure 2.7, shows how we detect the dynamic initial
value.
Figure 8.: Dynamic Initial Value Detection.
At this point, we need to find the best initial points of our data and proceed to develop
a non-linear statistical regression model. A good estimate of the parameters depends on
having the best possible initial points. We used the following basic initial values: minimum
response value for A, high response value for D, middle dose value for C, 5 for B, and 0.5
for g. Using those basic initial values, we applied them to a five parameters logistic model
using non-linear regression for the first replicated data through the last replicated data.
Before we used the replicated dose data, we also checked for outliers using the distance
theorem. We used the mean of each of the estimated parameters of replicated data for
the final initial values for the combined data set.Figure 9 shows the algorithm of the Drug
Efficiency Estimate program.
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Figure 9.: Algorithm of Drug Efficiency Estimate Program.
Outline step-by-step proceedure.
• Step 1. Use basic initial value to apply the five parameters logistic model on each
replicate result.
• Step 2. Save all estimated parameters for the dynamic initial value.
• Step 3. Apply the dynamic initial value to combined data set to estimate the five pa-
rameters.
• Step 4. If the minimum asymptote is less than zero, we apply the three parameters
logistic model.
• Step 5. calculate IC50 and ED50 value.
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2.6 Drug Efficiency Estimator Program
We made a graphic user interface(GUI) standalone program, which also included sample
data. We used a non-linear regression fit, the dynamic changing initial data points for
logistic models, and outlier detection for replicated experience. For outlier detection, we
used the distance theorem, and five, four, and three parameters logistic regression models
with the non-linear regression estimator.
Our GUI program has three parts. It consists a reading data part, drug experiment part,
saving result, scatter plot, and result curve plot. Data format must be followed by the
sample data format. The sample data is in a sample folder of our program package.Figure
10 shows the main figure of Drug Efficiency Estimate Program, and Figure 11 shows the
result of the Drug Efficiency Estimate Program.
The sample data which we used to get Figure 11 consisted of 12 independent drugs’
response data with three replicated experiments for each of the drugs. It has 10 dose levels.
Figure 10.: Main Figure of Drug Efficiency Estimate Program.
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Figure 11.: Result of Drug Efficiency Estimate Program.
Using this graphical result, we can see which drug(s) need more experimentation. For
example, Cell response of Drugs 2, 6, 9, 10, 11, 12 reach 0 % before they have a mini-
mum asymptote. In this case, medical scientists need to conduct more experimentation to
estimate their IC50 and ED50 values.
2.7 Compare with Commercial Program
We compared our program to the GraphPad Prism[13] which is a commercial program de-
veloped by GraphPad Software, Inc. There are several functions related to statistical com-
parisons, column statistics, lineage regression and correlation, nonlinear regression, and
clinical lab statistics. For comparison purposes, we focused on the nonlinear regression as-
pect. The GraphPad also includes an automatic outlier elimination and support replicates,
but the program uses only one mathematical model to estimate parameters; therefore, there
are large lack-of-fit errors when we apply the four parameters logistic model to asymmet-
rical data. Our program can estimate all the parameters for symmetric or asymmetric data,
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including non zero concentration. GraphPad doesn’t support dynamic initial values, and it
requires a manual input of basic initial values. The reason why manual input can pose a
problem is because there are un-identified parameters problems associated with it.
2.8 Summary and Contribution
In this Chapter, we introduced the four parameters logistic model, equation 2.1 and the five
parameters logistic model, equation 2.3. We showed the graphical parameters effect on the
five and four parameters logistic model. The four parameters logistic model is a special
case in five parameters logistic model when g is 1; however, we can only apply the four
parameter logistic model for symmetrical data. Therefore, there are many restrictions in
the four parameters logistic model because almost all the data is not symmetrical. Thus,
the purposed five parameters logistic model can handle asymmetrical medical data. There
are two types of resistance: the first one is when parameter B reaches O in the middle of
the dosage. In this case, we can’t estimate the IC50, but we can get the ED50. The second
type of resistance occurs when we have a negative estimated B parameter. In this case,
we proceed to estimate the parameters using the three parameters logistic model which is
a special case in the four parameters logistic model when B is 0. This program will give
medical scientists a scatter data plot, a fitted regression curve, and a result file which in-
cludes estimated parameters, indications for outliers, and indications for a need to continue
experimentation. Medical scientiests can reduce their time to obtain significant values for
IC50 or ED50 and easily view and compare the other new drug’s efficiency results. We
also provide the excel result file generated by our Drug Efficiency Estimater GUI program.
1. Obtain the optimal dose of a given drug using our Drug Efficiency Estomater GUI
program.
2. Dynamic initial start points for estimations.
3. Graphical and text result generated by our program.
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4. It calculate the most significant IC50 and ED50.
5. Outlier detection for unexpected experimentation using the distance algorithm.
6. Medical Scientists can easily use our GUI program to view and to compare their new
drug’s response.
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Chapter 3
Survival Analysis of Breast Cancer Data Using the Random Forests: an Ensemble of
Trees
3.1 Introduction
Tree-based methods by Bell(1999),[2] have become popular for performing survival anal-
ysis with complex data structures such as the SEER data obtained from SEER website,[8].
Within the Random Forest by Liaw(2002),[19], he applied the decision tree analysis by
Smith(2004),[29] to identify the most important attributable variables that significantly
contribute to estimating the survival time of a given cancer patient and proceeded to de-
velop a statistical model to estimate the survival time.
In this chapter, we present data mining techniques to make classified groups and rank
attributable variables using a weighted counting method. Data mining is the process of
analyzing large quantities of data and summarizing it into useful information.
According to WHO statistical reports by D.M. Parkin (2005),[6] the incidence of breast
cancer is the number one form of cancer among women. In the United States, approxi-
mately one in eight women over their lifetime have a risk of developing breast cancer. An
analysis of the most recent data has shown that the survival rate is 88% after 5 years of
diagnosis and 80% after 10 years of diagnosis, AMSWebite,[30]. Breast cancer occurs due
to an uncontrolled growth of cells in the breast tissues by BCF,[3] and damage to a cell’s
DNA, National Breast Cancer Center,[22]. A tumor is an abnormal cell growth that can
either be benign or malignant. Benign tumors are non invasive while malignant tumors
are cancerous and spread to other parts of the body. Early diagnosis and treatment help to
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prevent the spreading of cancer.
We are using breast cancer in the SEER data and have introduced the classification ap-
proach according to our research intereast.
In this chapter, we introduce the new decision tree algorithm and weighted counting
method for the final tree and rank of variables.
3.1.1 Introduction to Decision Tree
As simple as a decision tree may be, it is a very powerful form of multiple variable analysis
used with medical data, and especially cancer research. This is an extension of multiple
linear regression, and one of the data mining tools and techniques. In addition, decision
tree analysis has been used in many fields including financial, engineering, sports, and pres-
idential elections. It is produced by algorithms that identify the point for splitting a data set
into two groups. A decision tree can be used for classification (categorical variables) or re-
gression (continuous variables) applications. Rules are developed using software available
in many statistics packages. Different algorithms are used to determine the "best" split at
a node. We used the log rank test and the Kolmogorov-Smirnov test(K-S test) to find the
best split at a node.
A decision tree consists of a root node and branches. The root decision node is the
starting point of the tree, and the branches connect to their child nodes. If the child nodes
do not have their own child nodes, we called it a Terminal node. The general form of a
decision tree is illustrated in Figure 3.1.
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Figure 12.: Basic Decision Tree.
We can interpret the basic form of a sample decision tree in the following figures. The
above Figure 12 has three classified groups. The first group is consistent with patients in
stages I, II, and III at ages less than 50. The second group is consistent with patients in
stages I, II, III at ages greater than or equal to 50. The last group is consistent with patients
in stage IV.
There are several advantages to using a decision tree over other classification theory
tools such as neuro networking, because of its easy interpretability, simplicity, and short
time analysis.
3.1.2 Theory Behind Decision Tree Analysis
The basic idea of a decision tree analysis is to split the given source data set into subsets
by recursive portioning of the parent node into child nodes. This is based on the homo-
geneity of within-node instances or separation of between-node instances with respect to
target variables. For each node, attributes are examined and the splitter is chosen to be the
attribute such that after dividing the nodes into two child nodes, according to the value of
the attribute variable, the target variable is differentiated to be the best using an algorithm.
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Because of this, we need to be able to distinguish important attributes and those that con-
tribute little to the overall decision process. This process is repeated onto each child node in
a recursive manner until splitting is either non-feasible or all certain pre-specified stopping
rules are satisfied. Rpart, which is one of the R packages related to the decision tree, uses
complexity parameter(CP) to stop splitting.
Classification & Regression Tree is a decision tree algorithm (L. Breiman [18], 1984)
that is a non-parametric probability distribution tree technique that constructs binary clas-
sification or regression trees. Splitting points on attribute variables and choosing the best
variable are chosen based on Gini impurity and Gini gains following interesting interpre-
tation. If one object is selected at random from one of the C classes, according to the
probability (p1, p2, p3, · · · , pc), it is randomly assigned to a class using the same distribu-
tion. The probability of misclassification is given by,
Gini index p = ∑
j 6=k
Pi jPik = 1−∑
k
P2ik (3.1)
where ki is the most frequent class in node i.
If the target variable is continuous, the split criterion is used with the Least Squares
Deviation (LSD) as the impurity measure. If there is no Gini gain or the preset stopping rule
is satisfied, the splitting process stops. The CHAID (Chi-Squared Automatic Interaction
Detection) classification technique, introduced by Kass[17] (1980) for nominal predictors
and extended by Magidson [21] (1993) to ordinal predictors, is another effective approach
for nominal or ordinal target variables. CHAID exhausts all possible categorical pairs of
the target variable and merges each pair until there is no statistically significant difference
within the pair using the Chi-square test.
Suppose there are only two outcomes "Yes" or "No" in the root node T of the target vari-
able. Let p and n denote the number of positive records and negative records, respectively.
The initial information entropy is given by,
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I(p,n) =− p
p+n
log2
p
p+n
− n
p+n
log2
n
p+n
. (3.2)
If attribute X with values x1,x2, ...,xn is chosen to be the split predictor and partitions the
initial node into {T1,T2, ...,TN} and pi and ni denotes the number of positive records and
negative records in the child node i, then the expected information EI(X) and information
gain G(X) are given by,
EI(X) =
N
∑
i=1
pi +ni
p+n
I(pi,ni) (3.3)
and
G(X) = I(p,n)−EI(X), (3.4)
3.1.3 Random Forest
Random forest is an ensemble learning method developed by Leo Breiman and Adele Cut-
ler [? ] in 2001. Random forest offers more accuracy than the single-tree method, and
it gives us what variables are important in the classification. It can handle very large data
bases and thousands of input variables without variable deletion. The main idea is re-
sampling and simulation. Using bootstrap sample Di from training data set ( D ) with
replacement, we construct tree Ti using Di. At each node, we choose a random subset of
features, and only consider splitting on those features. Each tree gives us information for
prediction or classification. With all the information gained from the trees, we build the
final tree to interpret our data. We can also find the rank of variables using the weighted
counting method.
The following Figure 13 shows how to build the random forest using many decision
trees.
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Figure 13.: Systematic Diagram To Build Random Forest.
In the random forest building process, we use the following steps.
• Step 1. Select a variable
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• Step 2. Divide two groups and compare them using the log-rank test or K-S test.
• Step 3. Find the best split point on the selected variable.
• Step 4. We can also(Steps 1 4).
• Step 5. Decide the best variable and the split point which is the root node.
• Step 6. Steps 1 5 Repeating steps 1-5 using left child node data.
• Step 7. Steps 1 5 Repeat steps 1-5 using right child node data.
• Step 8. Continue to do Steps 1 7 until terminal nodes are reached.
In our R package, we have three options to choose the best split point and select variable.
The basic option is "Rpart" which is the most popular function in a decision tree. The
second option is "LRT" which uses the log-rank test. The third option is "KS" which uses
the Kolmogorov-Smirnov Test. In this chapter, we used the basic option to build the final
tree and ranking variables.
3.2 About Data
In the present study, we use breast cancer data given in the surveillance, epidemiology
and end results(SEER). The SEER data[8] is reliable because it is supported by the Na-
tional Cancer Institute(NCI). The SEER breast cancer incidence data consists of three
datasets named YR1973_2008.SEER9, YR1992_2008.sj_la_rg_ak, YR2000 _ 2008.ca_
ky_lo _nj _ga, YR2005.lo_2nd_half. The SEER currently collects and publishes cancer in-
cidences and survival data from population-based cancer registries covering approximately
28 percent of the US population as seen on the SEER Website[8]. Furthermore, the SEER
database is a premier source for cancer statistics in the United States, containing infor-
mation on incidence, prevalence and survival from specific geographical areas of the US
population. It also contains cancer mortality information for the entire country.
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Breast cancer occurs due to an uncontrolled growth of cells in the breast tissues. A tumor
is an abnormal cell growth that can either be benign or malignant. Benign tumors are non
invasive while malignant tumors are cancerous and spread to other parts of the body. An
analysis of the most recent data has shown that the survival rate is 85.98% after 5 years
and 80% after 10 years of diagnosis. Early diagnosis and treatments help to prevent the
spreading of cancer and improve the survival rate. Using random forests, we will make
classified groups to determine 5-year survival rate.
The ethnicity data size is shown by Figure 14 below.
Figure 14.: SEER Breast Cancer Diagram.
SEER 9 Breast cancer data includes three type of races. There are 496,153 Caucasians,
17,207 African Americans, and 33,434 Asians. The following Figure 15 shows the three
races’ information including three types of breast cancer which are ductal, medullary, and
lobular.
Ductal cancer is the most common type of breast cancer. According to the breast-
cancer.org, about 80% of all breast cancers are invasive ductal cancer. In our data set,
nearly 81% of cancers ductal breast cancer in Caucasians, about 83 % in African Ameri-
can, and 87% in Asian.
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Figure 15.: SEER Breast Cancer Histological Diagram.
Figure 16.: Normal Breast with Invasive Ductal Cancer : from www.breastcancer.org.
The following Figure 17 shows a systematic data diagram for breast cancer in Cau-
casians. Young and Chunling(2010) found that the age 50 is an important factor in breast
cancer. They also proved that there is a significant different among survival times for each
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race. This is why we are focusing on data obtained for Caucasians.
Figure 17.: SEER Breast Cancer Diagram : Caucasians.
3.3 Data pre-processing Methods
Data pre-processing by Han(2000),[14] is a significant issue in data mining studies. Data
preprocessing includes data cleaning, data transformation and data reduction. It is also the
process of discovering new patterns from large data sets by Chakrabarti(2009)[31]. Classi-
fication is a data mining technique based on machine learning which is used to classify each
item in a set of data into a set of predefined classes or groups by Han(2000),[14]. Classi-
fication methods in data mining make use of mathematical and statistical techniques such
as decision trees, linear programming, neural network and support vector machines. In the
present study, we used the data YR1073_2008.SEER9 for breast cancer data which consists
of 630,218 records with 124 variables. We will use the random forest technique that will be
discussed in the next section to identify and rank the most significant attributable variables
for survival time.
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3.4 Pre-Processing
Data pre-processing was applied to SEER data to prepare the raw data. Pre-processing is
an important step that is used to transform raw data into a format that makes it possible to
apply data mining techniques and to improve the quality of data[14]. It should be noted
from related work, that attribute selection plays an important role in identifying parameters
that are important and significant for proper breast cancer diagnosis. Data pre-processing
is followed by addressing the missing value and identifying or removing outliers. For
example, the tumor size variable contains values greater than 900 mm, which is abnormal
and thus, incorrect because of data entry errors, and; therefore, are removed. Another
example is that an extension of disease is an important factor in breast cancer survivability.
However,32.25% of our data was missing and unknown, therefore those records were also
removed. The following diagram shows steps to how we removed variables.
Figure 18.: Step-by-Step Procedure to Remove Non Significant Variables.
Feature selection is also implemented with logistic regression backward selection con-
ducted by using p-value> 0.1 as the exit criterion and p-value< 0.05 as the entry criterion.
After using these in data preprocessing, the final 6 discrete input variables are shown in
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Table 1. The final 7 numeric input variables are shown in Table 2. Predicting breast cancer
survivability is a binary classification problem, "survived" or "not survived". If survival
time recorded is equal to or more than 5 years, survival state indicates 0. If survival time
recorded is less than 5 years and the cause of death is breast cancer, survival status indicates
1, which means they did not survive. The dependent variable is survival status. Distribution
of the dependent variable is shown in Table 1. After data pre-processing there are 13 risk
factors, and 1 dependent variable named survival status. The total is 82,128 records and
13 variables. The percentage of "survived after 5 years" is 85.98% while it is reported in
NCI’s official data that in the United States the percentage of "survival after 5 years" was
88% in the year 2006.
Table 1: Description of Discrete Variables.
Variable Name Field Description Number of Dis-
tinct Value
MAR_ STAT Marital Status at Diagnosis 6
GRADE Grade 5
D_ AJCC_S AJCC Stage Group 11
RAD_SURG Radiation Sequence with Surgery 7
RAC_RECY Race 6
FIRSTPRM First Malignant Primary Indicator 2
Table 2: Basic Summary of Discrete Variables.
Variable Name Field Description Mean S.D. Range
AGE_DX Age at diagnosis 60.41 13.64 12-99
EOD10_PN Positive lymph nodes examined 1.15 3.13 0-84
EOD10_NE Number of lymph node examined 3.26 3.14 0-39
CS_SIZE CS Tumor size 20.75 20.98 0-922
CS_EXT CS Extension 0.89 7.67 0-70
CS_NODE CS Lymph Nodes 0.26 3.56 0-50
NUMPRIMS Number of Primaries 1.25 0.52 1-6
Figure 19 shows us the process of getting our final model for each of the groups.
After we have cleaned the data set, the first step is to select 80% of the sample from
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Figure 19.: Program Algorithm Flow Chart.
cleaned data. In this sampling, we used seed number 1234. Using 80% of the data, we
performed a bootstrapping and the decision tree method on our data. Our response variable
is a binary factor; therefore, we used the class method using Rpart which is a well known
package for a decision tree in R. The result of Rpart doesn’t include layer information,
so we need to use parsing which is a data mining technique in computer science. We
combined the C++ and R to do result parsing for selecting and ranking risk factors. A
frequency method is used to identify and select each layer’s variable(s) and find the best
point of each node. Once we obtained the final tree’s classification points, we classified
our data using end node information. Table 3 shows us the rank of our risk factors from the
first simulation.
The grade, number of primaries, race, and first malignant primary indicator are selected
less than 100 times during 1,000 simulations. Compared to other variables, those are not
important risk factors, so we do another 1,000 simulations using high rank risk factors
which are selected over 100 times as shown in Table 4. The order of rank is the same as
a previous simulation shown in Table 3. With this result, we confirmed that the order of
important risk factors is significant.
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Table 3: Rank for Risk Factors.
NumberVariable Field Description Freq.Sum
1 AGE_DX Age at diagnosis 549
2 CS_SIZE CS Tumor size 543
3 D_AJCC_S AJCC Stage Group 481
4 CS_NODE CS Lymph Nodes 277
5 EOD10_NE Negative lymph nodes examined 220
6 EOD10_PN Positive lymph nodes examined 220
7 MAR_STAT Marital Status at diagnosis 196
8 RAD_SURG Radiation sequence with surgery 129
9 GRADE Grade 96
10 NUMPRIMS Number of primaries 33
11 RAC_RECY Race 22
12 FIRSTPRM First malignant primary indicator 16
Table 4: Summary of Rank for Risk Factors.
NumberVariable Field Description Average
Freq.Sum
Standard
Deviation
1 AGE_DX Age at diagnosis 599 23.8
2 CS_SIZE CS Tumor size 557 19.2
3 D_AJCC_S AJCC Stage Group 527 19.1
4 CS_NODE CS Lymph Nodes 288 15.3
5 EOD10_NE Negative lymph nodes examined 272 15.2
6 EOD10_PN Positive lymph nodes examined 196 14.7
7 MAR_STAT Marital status at diagnosis 140 13.9
8 RAD_SURG Radiation sequence with surgery 130 13.2
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Figure 20.: Final Tree.
Figure 21.: Survival Curves using Final Classified Groups.
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We can clearly see different survival curves for the classified groups. G1 represents ages
that are less than 33, G2 shows ages that are less than 65 and greater than or equal to 33
and marriage state is two. G3 shows age less than 65 and greater than or equal to 33 and
marriage state is not two. G4 shows stage 1 and 2. G5 shows stage 3 and 4. The P-value in
log rank test is 0.03.
3.5 Validation of Procedure
For validation, we used a cross-validation method. We have data for two groups which are
the 80% data group, which we applied to our new approach, and the 20% data group. Each
group has 5 sub-groups. Logrank test is a statistical hypothesis test, where the hypothesis is
that the 2 groups have the same survival distribution. In particular, we divide the time into
m intervals. Let nk j be the number of individuals that are alive in group k at the beginning
of time interval j. Let dk j be the number of events occurring in group k during interval j.
Also, n j and d j are defined as Eq(3.5) and Eq(3.6),respectively.
n j =
n
∑
k=1
nk j, (3.5)
and
d j =
n
∑
k=1
dk j. (3.6)
The test statistic is calculated by the chi-squire test, that is,
χ2 =
n
∑
k=1
(Ok−Ek)2
Ek
, (3.7)
where Ok represents the number of observed deaths in group k, i.e.,
Ok =
m
∑
j=1
dk j, (3.8)
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and Ek is the expected number of deaths in group k,i.e.,
Ek =
n
∑
j=1
nk jd j
n j
. (3.9)
We performed 100 simulations and log-rank tests. The result of the log rank test for the
80% data and 20% data using random forest simulation is shown in Table 5.
Table 5: Log Rank Test.
Classified Group Average P-value Average S.D.
Group1: Age_dx≤ 33 0.083 0.01
Group2: 33≤ Age_dx≤ 65, MAR_STAT=2 0.077 0.008
Group3: 33≤ Age_dx≤ 65, MAR_STAT 6= 2 0.071 0.009
Group4: D_AJCC_S == 1or2 0.061 0.012
Group5: D_AJCC_S == 3or4 0.082 0.007
Following the result of the simulation, the average P-value of each group is greater than
0.05 and the average standard deviation is less than or equal to 0.01. There is no difference
between the two data sets which we used for our result and the rest of data.
3.6 Summary and Contribution
In this chapter, we proposed a new methodology using a randomized decision tree utiliz-
ing bootstrapping method for partitioning tree-based models to fit the SEER Breast Cancer
Dataset. Our proposal optimizes the way to rank our risk factors and to find the best classi-
fied points and risk factors for each node. We proposed a new pruning rule which is based
on minimizing the tree’s overall mean squared error, where labeling rule is based on iden-
tifying sub-groups of specific survival models. Using the Breast Cancer data, we validated
our method using simulation and a cross validation method.
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• Developed a new decision tree algorithm based on log-rank test and K-S test.
• Developed a new algorithm to rank risk factors using count and weighted count method.
• Proposed a method to validate our new method using cross validation and simulation.
• Developed generalized R functions which researchers can use and apply to all types of
data sets.
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Chapter 4
Estimating the Four Parameters Johnson-SB Probability Distribution: New R
Package
4.1 Introduction
The four parameter Johnson SB probability distribution is important in parametrically
studying a variety of health, environmental, and engineering problems. Scientists today
are experiencing difficulties in obtaining estimates for the four parameters of the subject
probability distribution.
Many methods have been developed to estimate the parameters of the Johnson probabil-
ity distribution, such as the four percentile method,Wheeler, Slifker and Shapiro [28], 1980.
The Knoebel-Burkhart method (Knoebel and Burkhart [27] , 1991) is another method to
obtain approximate estimates.
The aim of the present study is to review the existing methods to estimate the four pa-
rameters of the subject probability density function and to propose a fast algorithm that
produces better approximations for these parameters. The usefulness of this procedure is
illustrated using numerical simulation and real cancer data.
In the present study, we developed functions in the R package to generate random num-
bers and estimates for the four parameters, draw graphics, and analyze cancer data using the
Johnson SB probability distribution. We used normal transformations to generate random
numbers and the Newton-Raphson method to estimate the four parameters. In addition, we
incorporated general integration and a prediction procedure to draw useful graphs using R.
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4.2 Numerical Methods
In 1949, Johnson[16] proposed a system of three probability distributions based on trans-
formations of a standard normal probability distribution. The general form of the Johnson
system of distributions is given by
Z = γ+δ f (x;ξ ,δ ), (4.1)
with δ > 0, −∞< γ < ∞, δ > 0, −∞< ξ <−∞. (4.2)
Where Z is a standard normal variable and the random variable x followed the normal
probability density function f(x). Z must be specified, and it depends on a set of chosen
parameters. Bounded by (ξ ,ξ +λ ), The parameters γ and δ are the shape parameters, ξ
is the location parameter, and λ is the scale parameter. The values of these parameters
determine the shape and behavior of the probability distribution. Johnson suggested the
following functions, denoted by SL, SB, and SU , respectively,
f (x;ξ ,γ) = ln
(
x−ξ
γ
)
, x > ξ , (4.3)
f (x;ξ ,γ) = ln
(
x−ξ
γ+ξ − x
)
, ξ < x < ξ + γ, (4.4)
and
f (x;ξ ,γ) = sinh−1
(
x−ξ
γ
)
, −∞< x < ∞, (4.5)
We are interested in using the function given in equation (4.4), with the transformation
given by (4.1) to obtain,
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Z = γ+δ ln
(
x−ξ
γ+ξ − x
)
, ξ < x < ξ +λ , (4.6)
Since Z is a normally distributed random variable, the variable x is also identified as
log-normally distributed. The probability density function of x under the transformation,
(4.6), is given by
f (x) =
δ
λ
√
(2pi)y(1− y)exp
[
−1
2
{
γ+ξ
(
y
1− y
)2}]
, y =
x−ξ
λ
. (4.7)
Depending on the parameter values, the Johnson SB probability distribution has one or
more modes. Figure 22, displays the form of the distribution with the location set at 0 and
100 when the parameters (γ,δ ) have the values (0, 0.5), (0, 0.75), (0.25, 0.5), (0.5, 0.5), (1,
2), and (1, 1).
Figure 22.: Johnson’s SB distribution with (γ,δ ) combinations first row-left(0,0.5) ,first
row-middle(0,0.75), first row- right (0.25,0.5), second row-left(0.5,0.5),second row-middle
(1,2),second row-right (1,1).
In the JohnsonUSF package, we used the Newton-Raphson method to estimate the pa-
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rameters γ and δ . Using equation 4.7, the first and second partial derivatives with respect
to γ and δ are given by
∂L
∂γ
=−∑
x
(
γ+δ × log
(
y
1− y
))
, (4.8)
∂L
∂δ
=
n
δ
−∑
x
(
γ+δ × log
(
y
1− y
)
× log
(
y
1− y
))
, (4.9)
∂ 2L
∂γ2
=−n, (4.10)
∂ 2L
∂γ∂δ
=−∑
x
log
(
y
1− y
)
, (4.11)
and
∂ 2L
∂δ 2
=
−n
δ 2
−∑
x
(
log
(
y
1− y
))2
, y =
x−ξ
λ
(4.12)
In the JohnsonUSF package, the numerical procedure to estimate the four parameters of
the Johnson SB probability distribution(6) is displayed in the following steps.
Step 1 : Estimate ξ and λ using a quantile method.
Step 2 : Estimate γ and δ using a algorithm flow chart : Figure 23.
In the implementation of the algorithm, (β1, β2) represents the values of the vector
(γ,δ ) and is recursively updated in (β1∗ ,β1∗) using the following equation:
 β1∗
β2∗
=
 β1
β2
−H−1×S, (4.13)
where the Hessian Matrix H is given by
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Figure 23.: Algorithm to estimate the four parameters of the Johnson SB Probability Dis-
tribution.
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H =
 ∂ 2L∂γ2 ∂ 2L∂γ∂δ
∂ 2L
∂γ∂δ
∂ 2L
∂γ2
 (4.14)
and the score vector S is given by
S =
 ∂L∂γ
∂L
∂δ
 (4.15)
4.3 How to Use the JohnsonUSF Package
The JohnsonUSF package can be installed via the Install package(s) from the local zip files
option of the Packages menu (view Figure 24)
Figure 24.: Using local JohnsonUSF.zip file to install on your computer.
There are four parts in the JohnsonUSF package which generate random numbers, find
probability, critical values, and estimated parameters using several statistical methods.
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Table 6: Functions in JohnsonUSF Package.
Description Name of function
Generate Random Number rjohnsonsb(N,γ,δ ,λ ,ξ ,method)
Calculate Probability pjohnsonsb(q,tail)
Critical Value qjohnsonsb(p,tail)
Estimate Parameters est.johnsonsb(data,pl,method)
4.4 Validation of Estimated Parameters
We use the Kolmogorov-Smirnov (K-S), Anderson-Darling (A-D), and Chi-Squared good-
ness of fit tests for our random sample generated by theJohnsonUSF package. The first
statistical approach is based on the empirical cumulative distribution (ECD). The statistic
used in the K-S test relies on the largest vertical difference between the ECD and theoretical
function.
The second test is a modification of the K-S test and is not distribution-free since the
critical value of its statistic uses a specific distribution. The third test shows how the ob-
served value of a given "treatment" is significantly different from the observed value. For
example, using values δ = 3, γ = 4, ξ = 100, and λ = 0, ten thousand data sets of sample
size 1000 were generated. We proceed to estimate the parameter vector (δ ,γ) using the
JohnsonUSF package. The mean and standard deviation for each of the parameters are
given below in Table 7.
Table 7: Basic Statistics for the Parameters δ and γ for Ten Thousand Johnson SB Proba-
bility Distributed Random Samples.
δ = 3 γ = 4
Mean 3.004595 4.005728
Standard Deviation 0.0740135 0.0898567
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The following table shows result summaries of the K-S test for a sample with (δ ,γ) =
(3,4)
Table 8: Kolmogorov-Smirnov, Anderson-Darling, and Chi-Square goodness of fit test
results.
Kolmogorov-
Smirnov
Anderson-Darling Chi-Squared
Critial Value 0.01542 2.5018 21.0216
Alpha 0.05 0.05 0.05
Decision Fail to Reject H0 Fail to Reject H0 Fail to Reject H0
and Figure 25, below displays the histogram for the same random sample:
Figure 25.: Random Sample from JohnsonSB Probability Distribution δ = 3,γ = 4,ξ =
100,λ = 0.
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4.5 Apply to Real Lung Cancer Data
We used the JohnsonUSF package to estimate the parameters of the Johnson SB distribution
using real lung cancer data. The sample size for this data set was 7,754 corresponding
to lung cancer survival times. In addition, we employed the Easyfit program in order to
perform comparisons with respect to the results obtained using the JohnsonUSF package.
However, Easyfit will not give us any standard error information on each estimation nor
can it carry out a simulation study. The results are summarized in the following table:
Table 9: Estimate Comparison Using JohnsonUSF Package and Other Software Program.
δ γ ξ λ
EasyFit Result -0.133(NA) 0.73(NA) 284(NA) -6.8(NA)
JohnsonUSF -0.11(0.01) 0.72(0.031) 284(2) -6.8(0.8)
The corresponding histogram and the fitted curve for the estimates found by the proposed
JohnsonUSF package is shown in Figure 26.
4.6 Conclusion
We developed an R package for a four parameters JohnsonSB probability distribution. The
JohnsonUSF package includes generating random numbers, calculating probability and
inverse probability, and estimating four parameters for the JohnsonSB probability distribu-
tion. In a given population, we proceed to easily work with a four parameters JohnsonSB.
We progress to generate a sequence of random samples, and this package utilizes a loop
type of processor that can simultaneously generate random samples and estimates of cat-
egorical behavior of the distribution of each sample. This is something that the existing
method lacks and it requires extra work because each random sample information has to be
manually obtained. Statistician and student can use our package to easily develop research.
Our package will be kept up to date and developed using the following list.
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Figure 26.: Data Fitting Using Real Lung Cancer Data.
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• Apply MCMC to develop a random number generator and compare with previous study.
• Apply the E-M algorithm to obtain the parameter estimation, including censoring in-
formation.
• Develop a Bayesian model and apply the E-M algorithm to get parameters estimation.
4.7 Contribution
• Developed several functions such as probability, estimation, and graph related to the
JohnsonSB Probability Distribution.
• Applied several mixed algorithms to develop different functions.
• Developed R Packages using several functions.
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Chapter 5
Estimating Survival Time of Baseline Lung Cancer Using Statistical Modeling
5.1 Introduction
The purpose of the present study is to develop statistical models for predicting the survival
time and probability using data for lung cancer patients - USF Technical Report #100,
2010[31]. In this study, we used the number of cigarettes per day, duration of smoking, and
the age at diagnosis of lung cancer to identify the significant attributable variables including
their interactions, the survival time, and probability density functions for classified groups.
Cancer is the second leading cause of death and was among one of the first diseases
causally linked to smoking. In the United States, cigarette smoking causes approximately
438,000 deaths each year, including deaths related to cancer, cardiovascular disease, respi-
ratory disease and infant mortality. Compared to nonsmokers, men who smoke are about
23 times more likely to develop lung cancer and women who smoke are about 13 times
more likely. Smoking is the major determinant of lung cancer and accounts for 90% of all
cases. The relationship between smoking and lung cancer is well documented (Doll and
Peto[9], 1978; Doll et al.[26], 2004;IARC[11],2004), along with the benefits of smoking
cessation(US DHHS[23], 1990; Peto et al.[24], 2000). Many studies have focused on two
hypotheses: whether the combined effect of asbestos and smoking is addictive (each fac-
tor acts independently) or multiplicative (the effect of asbestos exposure on lung cancer
risk is proportional to the effect of smoking). In our research, the purpose of this study is
to identify the significant attributable variables as well as all possible interactions among
those variables. We also aim to construct a statistical model to predict the survival time as
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a function of those attributable variables and interactions so that we will be able to predict
how long a specific lung cancer patient will survive.
5.2 Lung Cancer Data with Smoking Information
Our intent is to analyze a data set consisting of 163,386 lung cancer patients with infor-
mation on survival time, sex, race, smoking indicate, number of cigarettes per day, du-
ration,and age at diagnosis. The five races indicated are Caucasian, African American,
Hispanic, Asian, and other. Sufficient data on race is not included in our data set. Although
our model is built almost entirely from data on Caucasians, we assume that racial differ-
ences are negligible. We also have former smoker and current smoker indicates. There is
one more assumption that one’s smoking history is continuous, e.q. no former smoker stat
again, and there are no ’gaps’ in a person’s smoking history.
The following Figure 27 Data Diagram of Lung Cancer Patient Informaton.
Figure 27.: Data Diagram of Lung Cancer’s Patients Information.
Our minimum survival time in months is 55 and the maximum survival time is 266; the
variance is 47.52; mean of average cigarettes per day is 25.04; minimum age at diagnosis
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is 32 years old while the average is 60.1 years old.
5.3 Classified Groups
We want to find out whether the true survival curves are different from current smoker and
former smoker including sex information. Compute the Mantel-Haenszel(1951) statistic
for those clissifiers to test those groups. There is strong evidencce to suggest that survival
time for all our groups are different, and its p-value is around 0.0001-0.0002.
We have the following four groups.
• Group 1 : Caucasian, Current Smoker, and Male.
• Group 2 : Caucasian, Current Smoker, and Female.
• Group 3 : Caucasian, Former Smoker, and Male.
• Group 4 : Caucasian, Former Smoker, and Female.
5.4 Correlation Matrix
We are addressing more than one independent variable. The collection of all zero-order
correlation coefficients can be represented most compactly in correlation matrix form. In
Group I, Time and CPD, DUR and AGEATIN demonstrate a positive correlation, and Time
and Dur, Time and AGEATIN, DUR and CPD, CPD and AGEATIN demonstrate a negative
correlation. The following tables give correlation matrices for group I.
Table 10: Correlation Matrix on Caucasian, Current Smoker, and Male (Group I).
Time CPD DUR AGEATIN
Time 1.00 0.63 -0.61 -0.88
CPD 0.63 1.00 -0.41 -0.61
DUR -0.61 -0.41 1.00 0.82
AGEATIN -0.88 -0.61 0.82 1.00
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In Group II, there is zero correlation between Time and CPD, and there are two positive
correlations on CPD and DUR, AGEATIN and DUR. There are three negative correlations
on Time and DUR, Time and AGEATIN, CPD and AGEATIN.
Table 11: Correlation Matrix on Caucasian, Current Smoker, and Female (Group II).
Time CPD DUR AGEATIN
Time 1.00 0.00 -0.73 -0.84
CPD 0.00 1.00 0.47 -0.03
DUR -0.73 0.47 1.00 0.79
AGEATIN -0.84 -0.03 0.79 1.00
In Group III, there are two positive correlations on Time and CPD, DUR and CPD.
There are three negative correlations on Time and DUR, Time and AGEATIN, CPD and
AGEATIN.
Table 12: Correlation Matrix White, Former Smoker, and Male (III).
Time CPD DUR AGEATIN
Time 1.00 0.08 -0.60 -0.65
CPD 0.08 1.00 0.13 -0.22
DUR -0.60 0.13 1.00 0.83
AGEATIN -0.65 -0.22 0.83 1.00
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In Group IV, there is one positive correlation on CPD and DUR, CPD and AGEATIN.
There are three negative correlations on Time and CPD, Time and DUR, Time and AGEATIN.
Table 13: Correlation Matrix on Caucasian, Former Smoker, and Female (IV).
Time CPD DUR AGEATIN
Time 1.00 -0.42 -0.66 -0.74
CPD -0.42 1.00 0.68 0.29
DUR -0.66 0.68 1.00 0.82
AGEATIN -0.74 0.29 0.82 1.00
The following figure shows the matrix of scatter plots for a groups.
Figure 28.: Matrix of Scatter Plots for All Groups.
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5.5 Survival Analysis and Statistical Modeling
The general purpose of multiple regressions (Pearson, 1908) is to learn more about the
relationship between several independent or predictor variables and a dependent or criterion
variable. The general form of the multiple regression model is given by equation 1, where
y is the response variable which is survival time to be estimated, and xi(t) and xi(t) are the
m different contributing entities i=1,2,3, m:
y = β0 +
m
∑
i=1
βiXi (t)+ ε (5.1)
In the proposed model, the descriptions of the contributing variables are provided in Ta-
ble 10, and these variables are denoted in equation 5.2 below. In equation 5.2, coefficients
β ′i s are the contributing variables, given in Table 9, and ε is the random error. The estimates
of the β ′i s are the key factors used to identify the significantly contributing variables.
m
∑
i=1
βiXi (t) =β1X1 +β2X2 +β3X3 (5.2)
Table 14: Variables Description .
Y Survival Time(Month)
x1 Number of Cigarettes Per Day
x2 Duration(year)
x3 Age at diagnosis
The maximum model is defined to be the largest model (having the most predictor vari-
ables) considered at any point in the process of model selection. All other possible models
can be created by deleting predictor variables from the maximum model. Created by delet-
ing predictors from the maximum model, our model is a restriction of the maximum model.
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5.5.1 Multiple Regression Model for Group I
Figure 29.: Matrix of Scatter Plots for Groups1.
From Figure 29,we can see that there is a positive linear relationship between time and age
and duration. Although monotonic, it may well be linear. We also have quadric behavior
between cigarettes per day and duration. Using this result, we can get a maximum model
for Group I given by,
Y1 = β0 +β1 x21 +β2 x1 +β3 x
2
2 +β4 x2 +β5 x3 +β6 x3
2 +
n
∑
i=7
int(x21,x1,x
2
2,x2,x
2
3,x3)+ ε
(5.3)
Using backward selection, we have the final model in 5.4
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ˆYg1 =−4202.01+527.82x1−159.37x2 +84.43x3−16.92x12 +3.82x22+
7.13x1 : x2−8.15x1 : x3 +1.96x2 : x3 +0.11x31−0.03x2 : x12+
0.21x3 : x12−0.42x1 : x22 +0.01x23−0.06x3 : x22 +0.01x12 : x22+
0.0018x13 : x3 (5.4)
With multiple regression comes an overall test of significance, and a multiple R2 which
is actually the value of r2 for the measured survival time vs. the predicted survival time.
Our multiple R-squared is 0.9971, and adjusted R-squared is 0.9953 for our final Group 1
model which is Caucasian, current smoker, and male.
The following Table 15 shows us part of the residual validation.
Table 15: Residual Validation : Group I (Mean residual : 0.075 and standard error : 0.95).
Actual Survival Time Estimated Survival Time Residual
1 884 883.44 -0.56
2 895 884.77 -0.23
3 839 840.56 1.56
4 864 864.07 0.07
5 929 929.13 0.13
6 849 850.72 1.72
7 802 802.46 0.46
8 907 905.73 -1.27
9 815 814.31 -0.69
10 930 929.55 -0.45
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5.5.2 Multiple Regression Model for Group II
Figure 30.: Matrix of Scatter Plots for Groups2.
From Figure 30,we can see that there is a positive linear relationship between time and age
and duration. Although monotonic, it may well be linear. We also have quadric behavior
between cigarettes per day and duration. Using this result, we can get a maximum model
for Group II given by,
Yg2 = β0 +β1 x21 +β2 x1 +β3 x
2
2 +β4 x2 +β5 x3 +β6 x3
2 +
n
∑
i=7
int(x21,x1,x
2
2,x2,x
2
3,x3)+ ε
(5.5)
Using backward selection, we have the final model in 5.6
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ˆYg2 =−9779.15+1898.28x1 +772.32x2 +187.12x3−114.36x12−6.06x22−
142.67x1 : x2−33.16x1 : x3−15.68x2 : x3+
2.2x13 +8.42x2 : x12 +1.98x3 : x12 +1.1x1 : x22−
0.08x23 +0.23x3 : x22−0.07x12 : x22 +2.89∗ x1 : x2 : x3 (5.6)
With multiple regression comes an overall test of significance, and a multiple R2 which
is actually the value of r2 for the measured survival time vs. the predicted survival time.
Our multiple R-squared is 0.9946, and adjusted R-squared is 0.9906 for our final Group 2
model which is Caucasian, current smoker, and female.
The following Table 16 shows us part of the residual validation.
Table 16: Residual Validation : Group II (Mean residual : -0.023 and standard error :
0.94).
Actual Survival Time Estimated Survival Time Residual
1 787 786.26 -0.74
2 902 902.68 0.68
3 946 945.04 -0.96
4 936 934.63 -1.37
5 782 781.50 -0.50
6 925 924.38 -0.62
7 807 807.94 0.94
8 841 841.23 0.23
9 905 905.67 0.67
10 936 937.43 1.43
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5.5.3 Multiple Regression Model for Group III
Figure 31.: Matrix of Scatter Plots for Groups3.
From Figure 31,we can see that there is a positive linear relationship between time and the
two factors, age and duration. Although monotonic, it may well be linear. We also have
quadric behavior between cigarettes per day and duration. Using this result, we can get a
maximum model for Group3 given by,
Yg3 = β0 +β1 x21 +β2 x1 +β3 x
2
2 +β4 x2 +β5 x3 +β6 x3
2 +
n
∑
i=7
int(x21,x1,x
2
2,x2,x
2
3,x3)+ ε
(5.7)
Using backward selection, we have the final model in 5.8
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ˆYg3 =12585.97−1041.6x1 +8300.3x2−166.42x3−50.3x12−91.94x22−
598.07x1 : x2 +11.66x1 : x3−124.55x2 : x3+
2.41x13 +16.1x2 : x12 +1.17x3 : x12 +5.81x1 : x22−
0.26x23 +1.88x3 : x22−0.14x12 : x22 +8.34x1 : x2 : x3 (5.8)
With multiple regression comes an overall test of significance, and a multiple R2 which
is actually the value of r2 for the measured survival time vs. the predicted survival time.
Our multiple R-squared is 0.9967, and adjusted R-squared is 0.9943 for our final Group 3
model which is Caucasian, former smoker, and female.
The following Table 17 shows us part of the residual validation.
Table 17: Residual Validation : Group III (Mean residual : -0.158 and standard error :
1.06).
Actual Survival Time Estimated Survival Time Residual
1 809 786.26 -0.77
2 860 902.68 0.93
3 778 945.04 0.47
4 923 934.63 -1.08
5 879 781.50 -2.16
6 658 924.38 -0.72
7 859 807.94 1.04
8 782 841.23 0.55
9 868 905.67 -0.61
10 817 937.43 0.77
61
5.5.4 Multiple Regression Model for Group IV
Figure 32.: Matrix of Scatter Plots for Groups4.
From Figure 32,we can see that there is a positive linear relationship between time and two
factors which are age and duration. Although monotonic, it well be linear. We also have
quadric behavior between cigarettes per day and duration. Using this result, we can get a
maximum model for Group4 given by,
Yg4 = β0 +β1 x21 +β2 x1 +β3 x
2
2 +β4 x2 +β5 x3 +β6 x3
2 +
n
∑
i=7
int(x21,x1,x
2
2,x2,x
2
3,x3)+ ε
(5.9)
Using backward selection, we have the final model in 5.10
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ˆYg4 =14.31+5.01x1 +8300.3x2 +14.1x3 +0.06x1 : x2−
−0.01x13 +0.02x2 : x22 (5.10)
With multiple regression comes an overall test of significance, and a multiple R2 which
is actually the value of r2 for the measured survival time vs. the predicted survival time.
Our multiple R-squared is 0.917, and adjusted R-squared is 0.888 for our final Group 4
model which is Caucasian, former smoker, and male.
The following Table 18 shows us part of the residual validation.
Table 18: Residual Validation : Group IV (Mean residual : -0.449 and standard error :
0.993).
Actual Survival Time Estimated Survival Time Residual
1 925 925.47 0.47
2 622 622.90 0.90
3 921 920.61 -0.39
4 880 878.06 -1.94
5 861 860.36 -0.64
6 902 902.32 0.32
7 862 861.26 -0.74
8 960 960.39 0.39
9 568 566.00 -2.00
10 783 782.14 -0.86
All four models provided high R-squares, ranging from 88%˜99%, which suggests that
these models provide good predictions for survival times of lung cancer patients.
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5.6 Fitting the Best Possible Probability Distribution
We proceeded to find the best possible probability distribution that characterizes the prob-
abilistic behavior of the survival times for each group. Using three goodness of fit test
methods, the Anderson-Darling Test(Anderson, Darling, 1951), Chi-Square Test(1954),
and Kolmogorov Smirnov Test(Kolmogorov, Smirnov, 1971), we ranked all possible prob-
ability distributions using the results from the goodness of fit tests.
5.6.1 Goodness of Fit Test for Group All
On the Anderson goodness of fit test, the ranks of best fit from first to third rank is a John-
son SB probability distribution with four parameters, Generalized Gamma probability dis-
tribution with four parameters, and Beta probability distribution with four parameters. On
the Chi-Squared Test, the ranks are Johnson SB probability distribution with four param-
eters, Power Function probability distribution, and Kumaraswamy probability distribution
with four parameters. On the Komogorov Smirnov Test, the ranks are Generalized Gamma
probability distribution with three parameters, Dagum probability distribution, and Wakeby
probability distribution.
A summary of the rankings for the goodness-of-fit tests for Group I is shown in Table 19
below,
Table 19: Summary of Goodness-of-fit Test for Group All.
Distribution Anderson Darling Distribution Chi-Squared Distribution Kolmogorov Smirnov
Statistics Rank Statistics Rank Statistics Rank
Johnson SB 5.1648 1 Johnson SB 75.286 1 Wakeby 0.00607 1
Gen.Gamma(4p) 6.7065 2 Beta 202.79 2 Johnson SB 0.00734 2
Beta 16.081 3 Kumaraswamy 162.32 3 G.. Gamma(4p) 0.00916 3
Evaluating the result of the goodness-of-fit tests is the four parameter Johnson SB proba-
bility distribution with MLE given by (γ =−1.7143,δ = 1.3379,λ = 668.27,ξ = 322.74).
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f (x) =
δ
λ
√
2piz(1− z)exp(−
1
2
(
γ+δ ln
(
z
1− z
) )2
(5.11)
where z = x−ξλ , γ and δ are shape parameters and λ is scale parameter ξ is location
parameter, and the domain is ξ ≤ x ≤ ξ + λ . The estimated form of the subject PDF is
given by,
ˆf (t) =
1.3379
686.27
√
2piz(1− z)exp(−
1
2
(
−1.7143+1.3379ln
(
z
1− z
) )2
, Z ≡ t−322.74−1.7143
(5.12)
Thus, the parametric survival function for Group All is given by,
ˆS(t) = 1−F(t) = 1−Φ
(
−1.7143+1.3379
(
Z
1− z
))
, Z ≡ t−322.74−1.743 (5.13)
The graph of the survival function S(t) for the group all is given below, in Figure 33
Figure 33.: Compare Survival Function with Parametric Method and K-M in Group All.
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5.6.2 Goodness of Fit Tests for Group I
Based on the Anderson Darling goodness-of-fit test, the best is the Generalized extreme
value probability distribution; the second best is the Log-Pearson probability distribution
with three parameters; the third best is the Beta probability distribution with four param-
eters. Using the Chi-Squared Test, the first is the Generalized extreme value probability
distribution; the second is the Log-Pearson probability distribution with three parameters;
the third best is the Johnson SB probability distribution with four parameters. From the
Komogorov Smirnov Test, the best is the Wakeby probability distribution; the second best
is the Generalized Extreme value probability distribution; the third probability distribution
is the Beta probability distribution.
Summary of the rankings of goodness-of-fit tests for Group I is given by Table 20 below,
Table 20: Summary Of Goodness-of-fit Test For Group I.
Distribution Anderson Darling Distribution Chi-Squared Distribution Kolmogorov Smirnov
Statistics Rank Statistics Rank Statistics Rank
Gen. Ext. Value 0.0782 1 Gen. Ext. value 71.821 1 Wakeby 0.012 1
Log-Pearson 3 0.024 2 Log-Pearson 3 110.95 2 Gen. Ext. Value 0.019 2
Beta 0.021 3 Johnson SB 175.35 3 Beta 0.021 3
Evaluating the result of the goodness-of-fit tests is the Generalized extreme value prob-
ability distribution with MLE given by (kˆ = −0.62429, σˆ = 96.18, and µˆ = 827.85). The
analytical form of the subject PDF is given by,
f (t) =

1
σ exp(−(1+ k z)−1/k))(1+ kz)−1−1/k, k 6= 0
1
σ exp(−z− exp(−z)), k = 0,
(5.14)
where z ≡ t−µσ , k is continuous a shape parameter, σ is a continuous scale parameters,
and µ is a continuous location parameter. The estimated form of the subject PDF is given
by,
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ˆf1(t) =
1
96.18
exp(−(1−0.624t−827.85
96.18
)1.603)(1−0.624t−827.85
96.18
)0.603, (5.15)
Thus, the parametric survival function for Group I is given by,
ˆS1(t) = 1−F2(t) = 1− exp−(1−0.624t−827.8596.18 )
1.603
(5.16)
The graph of the survival function S1(t) for Group I is given below, by Figure 34
Figure 34.: Compare Survival Function with Parametric Method and K-M in Group I.
There is a significant difference after 600 months of survival time between overall sur-
vival curve and Group I.
5.6.3 Goodness of Fit Test for Group II
Based on the Anderson Darling goodness-of-fit test, the best is the Generalized extreme
value probability distribution; the second best is the JohnsonSB probability distribution
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with four parameters; the third best is the Kumaraswamy probability distribution. Using
the Chi-Squared Test, the first is the Generalized extreme value probability distribution; the
second is the the Johnson SB probability distribution with four parameters; the third best is
Log-Pearson probability distribution with three parameters. From the Komogorov Smirnov
Test, the best is the Wakeby probability distribution; the second best is the Pert probability
distribution; the third best probability distribution is the Beta probability distribution.
Summary of rankings of goodness-of-fit test for Group II is given by Table 21, below,
Table 21: Summary of Goodness-of-fit test for Group II.
Distribution Anderson Darling Distribution Chi-Squared Distribution Kolmogorov Smirnov
Statistics Rank Statistics Rank Statistics Rank
Gen. Ext. Value 0.0782 1 Gen. Ext. value 58.1 1 Wakeby 0.012 1
Johnson SB 0.027 2 Johnson SB 106.13 2 Pert 0.018 2
Kumaraswamy 0.027 3 Log-Pearson 3 129.74 3 Beta 0.02 3
Evaluating the result of the goodness-of-fit tests is the Generalized extreme value prob-
ability distribution with MLE given by (kˆ = −0.609, σˆ = 98.448, and µˆ = 820.39). The
analytical form of the subject PDF is given by,
f (t) =

1
σ exp(−(1+ k z)−1/k))(1+ kz)−1−1/k, k 6= 0
1
σ exp(−z− exp(−z)), k = 0,
(5.17)
where z ≡ t−µσ , k is continuous a shape parameter, σ is a continuous scale parameters,
and µ is a continuous location parameter. The estimated form of the subject PDF is given
by,
ˆf2(t) =
1
98.448
exp(−(1−0.606t−820.39
98.448
)1.642)(1−0.606t−820.39
98.448
)0.642, (5.18)
Thus, the parametric survival function for Group II is given by,
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ˆS2(t) = 1−F2(t) = 1− exp(−1−0.606t−820.3998.448 )
1.642
(5.19)
The graph of the survival function S2(t) for Group II is given below, by Figure 35
Figure 35.: Compare Survival Function with Parametric Method and K-M in Group II.
There is a significant difference in 600-920 months of survival time between overall
survival curve and Group II.
5.6.4 Goodness of Fit Test for Group III
Based on the Anderson Darling goodness-of-fit test, the best is the Pert probability distribu-
tion; the second best is the Generlized extream value probability distribution; the third best
is the JohnsonSB probability distribution with four parameters. Using the Chi-Squared
Test, the first is the Pert probability distribution; the second is the the Beta probability
distribution with four parameters; the third best is the the Generlized extream value proba-
bility distribution. From the Komogorov Smirnov Test, the best is the Wakeby probability
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distribution; the second best is the Pert probability distribution; the third best probability
distribution is the Beta probability distribution.
Summary of rankings of goodness-of-fit test for Group III is given by Table 22, below,
Table 22: Symmary of Goodness-of-fit Test For Group III.
Distribution Anderson Darling Distribution Chi-Squared Distribution Kolmogorov Smirnov
Statistics Rank Statistics Rank Statistics Rank
Pert 38.846 1 Pert 160.2 1 Wakeby 0.016 1
Gen. Ext. Value 38.214 2 Beta 237.51 2 Pert 0.016 2
Johnson SB 0.0307 3 Gen. Ext. Value 247.52 3 Beta 0.017 3
Evaluating the result of the goodness-of-fit tests is the pert probability distribution with
MLE given by (mˆ = 924.66, aˆ = 417, and bˆ = 966). The analytical form of the subject PDF
is given by,
f (t) =
1
B(α1,α2)
(t−a)α1−1(b− t)α2−1
(b−a)α1+α2−1 , (5.20)
where B is the Beta Function which is
B(α1,α2) =
∫ 1
0
tα1−1(1− t)α2−1dt (α1, α2 > 0), (5.21)
m(most likely value) - cuntinuous mode parameter (a≤m≤ b), a and b are contunuous
boundary parameters (a < b), α1 = 4m+b−5ab−a = 4.7, and α2 =
5b−a−4m
b−a = −5.13. The
estimated form of the subject PDF is given by,
ˆf3 (t) =
1
B(4.7,−5.13)
(t +417)3.7(966− x)−6.13
(1383)−1.43
, (5.22)
Thus, the parametric survival function for Group III is given by,
ˆS3(t) = 1−F3(t) = 1− Iz(4.7,−5.13). (5.23)
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where Z ≡ t−ab−a ,B is the Beta Function, and Iz is the Regularized Incomplete Beta Func-
tion.
The graph of the survival function S3(t) for Group III is given below, by Figure 36
Figure 36.: Compare Survival Function with Parametric Method and K-M in Group III.
There is a significant difference after 760 months of survival time between the overall
survival curve and Group III.
5.6.5 Goodness of Fit Test for Group IV
Based on the Anderson Darling goodness-of-fit test, the best is the Beta probability distri-
bution with four parameters; the second best is the Generlized extream value probability
distribution; the third best is the Pert probability distribution. Using the Chi-Squared Test,
the first is the Log-Person probability distribution with three parameters; the second is the
the Generlized extream value probability distribution; the third best is the Beta probability
distribution with four parameters probability distribution. From the Komogorov Smirnov
Test, the best is the Beta probability distribution with four parameters; the second best is
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the Wakeby probability distribution; the third best probability distribution is the Pert prob-
ability distribution.
Summary of rankings of goodness-of-fit test for Group IV is given by Table 23, below,
Table 23: Summary of Goodness-of-fit Test For Group IV.
Distribution Anderson Darling Distribution Chi-Squared Distribution Kolmogorov Smirnov
Statistics Rank Statistics Rank Statistics Rank
Beta 12.049 1 Log-Person 3 40.175 1 Beta 0.014 1
Gen. Ext. Value 12.845 2 Gen. Ext. Value 41.72 2 Wakeby 0.015 2
Pert 0.0169 3 Beta 44.966 3 Pert 0.017 3
Evaluating the result of the goodness-of-fit tests is the pert probability distribution with
MLE given by (α1 = 4.6829, α2 = 1.1474, a = 382, and b = 966),
f (t) =
1
B(α1,α2)
(t−a)α1−1(b− t)α2−1
(b−a)α1+α2−1 , (5.24)
where B is the Beta Function which is
B(α1,α2) =
∫ 1
0
tα1−1(1− t)α2−1dt (α1, α2 > 0), (5.25)
α1 and α2 are shape parameters and a and b are boundary parameters (a < b). The
estimated form of the subject PDF is given by,
ˆf4 (t) =
1
B(4.68,1.15)
(t−382)3.68(966− x)0.15
(584)4.83
, (5.26)
Thus, the parametric survival function for Group IV is given by,
ˆS4(t) = 1−F4(t) = 1− Iz(4.68,1.15). (5.27)
where Z ≡ t−ab−a ,B is the Beta Function, and Iz is the Regularized Incomplete Beta Func-
tion.
72
The graph of the survival function S4(t) for Group IV is given below, by Figure 37
Figure 37.: Compare Survival Function with Parametric Method and K-M in Group IV.
There is a significant difference after 720 months of survival time between the overall
survival curve and Group IV.
The graph of the survival function for the groups and overall survival curve is given
below, by Figure 38
Figure 38.: Compare Survival Curve Between Groups And Overall Survival Time.
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The green curve shows the overall survival curve. The red and yellow curves are current
smoking groups, and the purple and orange curves are former smoking groups. From the
survival curve, there is a significant difference between current smoking groups and former
smoking groups. Furthermore, the survival rate in current smoking groups is lower than
the overall survical curve, and the survival rate of former smoking groups are higher than
overall survival curve with current smoking groups.
5.7 Conclusion and Contributions
We proceeded to investigate the relationship between survival time and other attributable
variables, such as number of cigarettes per day, duration, and age at diagnosis where a mul-
tiple regression model is the most commonly used tool. We applied several transformation
methods and included polynomial terms; we obtained our final four models which provide
a good R-square measure, which will be useful to predict survival times in lung cancer
patients. From the results of the Goodness of fit tests, we ranked the 65 distributions using
the Kolmogorov Smirnov, Anderson Darling, and Chi-Squared Test. We found the best
possible probability distribution for each of the groups among the 65 distributions. There
is a significant difference between groups and the overall survival curves.
Using our results, we could calculate a lung cancer patient’s survival time and probability
information using number of cigarettes per day, duration, and age at diagnosis, by using our
final models and probability density distributions.
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Table 24: Summary of Mathematical Models, Probability Density and Survival Function.
Mathematical Functions
Group I
Yˆ1 = −4202.01+527.82∗ x1−159.37∗ x2+84.43∗ x3−16.92∗ x12 +3.82∗ x22
+ 7.13∗ x1 : x2−8.15∗ x1 : x3+1.96∗ x2 : x3
+ 0.11∗ x13−0.03∗ x2 : x12 +0.21∗ x3 : x12−0.42∗ x1 : x22
+ 0.01∗ x23−0.06∗ x3 : x22 +0.01∗ x12 : x22 +0.0018∗ x13 : x3
ˆf1(t) = 196.18 exp(−(1−0.624 t−827.8596.18 )1.603)(1−0.624 t−827.8596.18 )0.603
ˆS1(t) = 1−F1(t) = 1− exp−(1−0.624 t−827.8596.18 )
1.603
Group II
Yˆ2 = −9779.15+1898.28∗ x1+772.32∗ x2+187.12∗ x3−114.36∗ x12−6.06∗ x22
+ 142.67∗ x1 : x2−33.16∗ x1 : x3−15.68∗ x2 : x3+
+ 2.2∗ x13 +8.42∗ x2 : x12 +1.98∗ x3 : x12 +1.1∗ x1 : x22−
+ 0.08∗ x23 +0.23∗ x3 : x22−0.07∗ x12 : x22 +2.89∗ x1 : x2 : x3
ˆf2(t) = 198.448 exp(−(1−0.606 t−820.3998.448 )1.642)(1−0.606 t−820.3998.448 )0.642
ˆS2(t) = 1−F2(t) = 1− exp(−(1−0.606 t−820.3998.448 ))
1.642
Group III
Yˆ3 = 12585.97−1041.6∗ x1+8300.3∗ x2−166.42∗ x3−50.3∗ x12−91.94∗ x22−
+ 598.07∗ x1 : x2+11.66∗ x1 : x3−124.55∗ x2 : x3+
+ 2.41∗ x13 +16.1∗ x2 : x12 +1.17∗ x3 : x12 +5.81∗ x1 : x22−
+ 0.26∗ x23 +1.88∗ x3 : x22−0.14∗ x12 : x22 +8.34∗ x1 : x2 : x3
ˆf3 (t) = 1B(4.7,−5.13)
(t+417)3.7(966−x)−6.13
(1383)−1.43
ˆS3(t) = 1−F3(t) = 1− Iz(4.7,−5.13)
Group IV
Yˆ4 = 14.31+5.01∗ x1+8300.3∗ x2+14.1∗ x3+0.06∗ x1 : x2−
+ −0.01∗ x13 +0.02∗ x2 : x22+
ˆf4 (t) = 1B(4.68,1.15)
(t−382)3.68(966−x)0.15
(584)4.83
ˆS4(t) = 1−F4(t) = 1− Iz(4.68,1.15)
Group All ˆf (t) = 1.3379
686.27
√
2piz(1−z)exp(−
1
2
(−1.7143+1.3379ln( z1−z) )2 , Z ≡ t−322.74−1.7143
ˆS(t) = 1−F(t) = 1−Φ(−1.7143+1.3379( Z1−z)) , Z ≡ t−322.74−1.743
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Figure 39.: Estimated Survival Time and Probability with Three factors.
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Chapter 6
Future Research Projects
We introduced the four parameters logistic model in equation 2.1 and the five parame-
ters logistic model in equation 2.3. We showed the graphical parameters and their effects
on the five and four parameters logistic models. The four parameters logistic model is
a special case in a five parameters logistic model when g is 1. We can, however, apply
the four parameter logistic model for symmofficiantetrical data. This proves that there are
many restrictions in the four parameters logistic model because most data simply are not
symmetrical. On the other hand, the proposed five parameters logistic model can handle
asymmetrical medical data. There are two types of resistance: the first one being the pa-
rameter B reaches O in the middle of the dosage. In this case, we cannot estimate the IC50,
but we can estimate the ED50. The second type of resistance occurs when the estimated B
parameter is negative. In this case, we proceed to estimate the parameters using the three
parameters logistic model, which is a special case in the four parameters logistic model
when B is 0. This program will give medical scientists scatter data plots, a fitted regression
curve, and a result file which includes estimated parameters, indications of outliers, and
indication of a need to continue experimentation. Medical scientists can reduce time spent
on obtaining significant values for IC50 or ED50 and can easily view and compare results
with new and other drug efficiencies. We also provided the excel result file generated by
our Drug Efficiency Estimater GUI program. We propose to keep this program up to date
and input new statistical functions on this software for medical scientists and researchers.
We also proposed to introduce new methodology using a randomized decision tree by
utilizing bootstrapping methods to partition tree-based models to fit the SEER Breast Can-
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cer Dataset. Our proposed method is to rank the risk factors and to find the best classified
points and risk factors for each node. We also propose to study a new pruning rule by
minimizing the tree’s overall mean squared error, and a new labeling rule based on identi-
fying subgroups of specific survival models. Using Breast Cancer data, we will be able to
validate our proposed method using simulations and a internal cross validation procedure.
When another cancer data set is received, we will conduct an external cross validation to
check the effectiveness of our developed method.
We developed an R package for a four parameters JohnsonSB probability distribution.
The JohnsonUSF package includes generating random numbers, calculating probabilitie,
and inverse probabilities, and estimating the four parameters for the JohnsonSB probability
distribution. We propose to develope a process to generate a sequence of random sam-
ples, with a package that utilizes a loop type of processor that can simultaneously generate
random samples and estimates of categorical behavior of the probability distribution of
each sample. Presently, there is no method to efficiently obtain information for each of the
random samples.The proposed development of each package will allow scientists to:
• Apply MCMC to develop random number generators to compare previous studies.
• Apply the E-M algorithm to obtain the parameter estimations, including censoring in-
formation.
• Develop a Bayesian model and apply the E-M algorithm to obtain bayesian parameter
estimatis.
We propose to investigate the relationship between survival time and other attributable
variables, such as number of cigarettes per day, duration, and age at diagnosis where a
multiple nonlinear regression models will generate the survival times predict to these such
factors. With the development of such nonlinear statistical model, we should be able to
rank the target contributable variable to the smallest significant risk factor. Once we have
developed and evaluated the accuracy of the proposed model using R and R adjusted and
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residual analysis, we will proceed to use surface response analysis to determinate the values
of the risk factors that will maximize the survival time of a cancer patient.
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